Global News

DARPA awards Inovio $45M Ebola program grant

Thursday, April 9, 2015 01:43 PM

Inovio Pharmaceuticals, based in Plymouth Meeting, Pa., has been awarded a $45 million grant from the Defense Advanced Research Projects Agency (DARPA) to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola.

More... »

Quest Diagnostics

Roche becomes majority shareholder in Foundation Medicine

Thursday, April 9, 2015 01:41 PM

Roche has become a majority shareholder of Foundation Medicine, a molecular information company based in Cambridge, Mass. Roche purchased approximately 15.6 million shares of common stock through a tender offer from Foundation Medicine stockholders at a price of $50 per share.

More... »


Mylan proposes to acquire Perrigo for $205 per share

Thursday, April 9, 2015 01:36 PM

Mylan, a global generics and specialty pharmaceutical company, has made a proposal to acquire Perrigo, an Irish international manufacturer of over-the-counter pharmaceuticals, in a cash-and-stock transaction.

More... »

Rhythm initiates phase IIb clinical trial of relamorelin for diabetic gastroparesis

Thursday, April 9, 2015 12:59 PM

Rhythm, a biopharmaceutical company, and Actavis, a global pharmaceutical company, have initiated a phase IIb clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal (GI) motility. Actavis has an exclusive option to acquire Rhythm's wholly owned subsidiary, Rhythm Pharmaceuticals, upon the completion of the phase IIb study.

More... »

Celtaxsys to begin phase II trial of oral CTX-4430 for acne vulgaris

Thursday, April 9, 2015 12:48 PM

Atlanta-based pharmaceutical company Celtaxsys has received regulatory clearance to commence a phase II trial for its flagship compound, CTX-4430, in patients with moderate to severe facial acne vulgaris. This approval triggers site engagement to screen and enroll appropriate patients with acne.

More... »

Bristol-Myers Squibb, uniQure collaborate on gene therapies for cardiovascular diseases

Wednesday, April 8, 2015 01:03 PM

Bristol-Myers Squibb has inked an agreement with uniQure, a gene therapy developer based in the Netherlands, for exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases.

More... »

TrialScope launches free EudraCT results conversion service

Wednesday, April 8, 2015 12:58 PM

TrialScope, a New Jersey-based provider of clinical trial transparency and compliance solutions, has launched Convert, a free online clinical trial data conversion service. The complimentary service enables users to quickly and efficiently reuse clinical trial results data that previously was reported to the U.S. registry (clinicaltrials.gov) and convert it to the appropriate format for submission to the European registry (EudraCT).

More... »

National MS Society invests $28M in MS research

Wednesday, April 8, 2015 12:55 PM

The National Multiple Sclerosis Society has committed $28 million to support an expected 84 new multiple sclerosis (MS) research projects and training awards. These are part of a comprehensive research strategy aimed at stopping MS, restoring function that has been lost and ending the disease.

More... »

LabConnect expanding advanced laboratory operations center in Tennessee

Wednesday, April 8, 2015 12:54 PM

LabConnect, a global provider of central laboratory services, will be moving its operations center in Johnson City, Tenn., to a new, 42,000-square-foot custom-built facility effective May 7. LabConnect’s laboratory testing facility in Johnson City will remain in its current location.

More... »

CRISPR Therapeutics to establish R&D operations in Massachusetts

Wednesday, April 8, 2015 12:42 PM

CRISPR Therapeutics, a Switzerland-based biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines for serious human diseases, has appointed Bill Lundberg, M.D., to chief scientific officer to lead the company's development programs and to spearhead the creation of its R&D operations in Cambridge, Mass.

More... »

`

CWWeekly

April 20

Christie Clinic, PMG Research's 12th clinical research site, expands its geographic reach north to Illinois

Clinipace acquires Accovion to expand European presence, following an infusion of equity that could lead to more deals

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs